CL2022001937A1 - Anti-pmel17 antibodies and conjugates thereof (divisional 202101607) - Google Patents
Anti-pmel17 antibodies and conjugates thereof (divisional 202101607)Info
- Publication number
- CL2022001937A1 CL2022001937A1 CL2022001937A CL2022001937A CL2022001937A1 CL 2022001937 A1 CL2022001937 A1 CL 2022001937A1 CL 2022001937 A CL2022001937 A CL 2022001937A CL 2022001937 A CL2022001937 A CL 2022001937A CL 2022001937 A1 CL2022001937 A1 CL 2022001937A1
- Authority
- CL
- Chile
- Prior art keywords
- antibodies
- antigen
- binding fragments
- antibody
- methods
- Prior art date
Links
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente solicitud describe anticuerpos anti-PMEL17, fragmentos de unión a antígeno de los mismos, y conjugados de anticuerpo fármaco de dichos anticuerpos o fragmentos de unión a antígeno conjugados a un inhibidor de GNAQ/GNA11. La invención además se refiere a métodos para tratar o prevenir el cáncer usando los anticuerpos, fragmentos de unión a antígeno, y conjugados de anticuerpo fármaco. Además se describen métodos de preparación de anticuerpos, fragmentos de unión a antígeno, y conjugados de anticuerpo fármaco, y métodos de uso de los anticuerpos y fragmentos de unión a antígeno como reactivos de diagnóstico.The present application describes anti-PMEL17 antibodies, antigen-binding fragments thereof, and antibody-drug conjugates of such antibodies or antigen-binding fragments conjugated to a GNAQ/GNA11 inhibitor. The invention further relates to methods of treating or preventing cancer using the antibodies, antigen-binding fragments, and antibody-drug conjugates. Further described are methods of preparing antibodies, antigen-binding fragments, and antibody-drug conjugates, and methods of using the antibodies and antigen-binding fragments as diagnostic reagents.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CL2022001937A CL2022001937A1 (en) | 2022-07-18 | 2022-07-18 | Anti-pmel17 antibodies and conjugates thereof (divisional 202101607) |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CL2022001937A CL2022001937A1 (en) | 2022-07-18 | 2022-07-18 | Anti-pmel17 antibodies and conjugates thereof (divisional 202101607) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2022001937A1 true CL2022001937A1 (en) | 2023-04-10 |
Family
ID=86337435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2022001937A CL2022001937A1 (en) | 2022-07-18 | 2022-07-18 | Anti-pmel17 antibodies and conjugates thereof (divisional 202101607) |
Country Status (1)
| Country | Link |
|---|---|
| CL (1) | CL2022001937A1 (en) |
-
2022
- 2022-07-18 CL CL2022001937A patent/CL2022001937A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021001607A1 (en) | Anti-pmel17 antibodies and conjugates thereof | |
| CY1121254T1 (en) | ANTI-CTLA-4 ANTIBODIES COMPOSITIONS | |
| BR112021023229A2 (en) | mcl-1 inhibitor antibody-drug conjugates and methods of use | |
| ES2328474T3 (en) | ISCOM PREPARATION AND ITS USE. | |
| BR112021008060A2 (en) | Polypeptide, anti-ctla4 antibody or antibody fragment, immunoconjugate, pharmaceutical composition, single dose of pharmaceutical composition, method of treating cancer, and, kit for diagnosis or treatment | |
| CO2022003582A2 (en) | Methods for the treatment of thyroid ophthalmopathy | |
| BR112022024833A2 (en) | ANTI-BCMA-DRUG ANTIBODY CONJUGATES AND METHODS OF USE | |
| CO2023002375A2 (en) | Antibodies against ilt2 and use thereof | |
| CO2022002573A2 (en) | Antibodies against ilt2 and their use | |
| BR112021016596A2 (en) | Anti-pd-l1 antibody and its use | |
| PE20231104A1 (en) | BRM ANTIBODY CONJUGATED CHEMICAL DEGRADATION INDUCERS AND METHODS THEREOF | |
| ECSP23073625A (en) | ANTI-NECTIN-4 ANTIBODY AND EXATECANE CONJUGATES | |
| CO2023004110A2 (en) | Anti-fgfr2 antibodies and methods of using them | |
| CL2022001937A1 (en) | Anti-pmel17 antibodies and conjugates thereof (divisional 202101607) | |
| CO2021017477A2 (en) | combination therapy | |
| CO2023016712A2 (en) | Neodegrader-anti-cd33 antibody conjugates | |
| BR112023000455A2 (en) | TREATMENT OF INFLAMMATORY DISEASE USING ANTI-TISSUE FACTOR ANTIBODIES | |
| BR112023021475A2 (en) | ANTIBODY-DRUG CONJUGATES AND METHODS FOR PRODUCING THEM | |
| BR112022009672A2 (en) | TREATMENT OF CANCER WITH ANTIBODY-DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | |
| CL2023000084A1 (en) | Anti-betacellulin antibodies, fragments thereof, and multispecific binding molecules | |
| BR112022024361A2 (en) | TUBULISINS AND PROTEIN-TUBULISIN CONJUGATES | |
| AR122660A2 (en) | ANTI-PMEL17 ANTIBODIES AND CONJUGATES THEREOF | |
| BR112022024691A2 (en) | BISPECIFIC ANTIBODY CONJUGATES - DRUG TARGETED TO EGFR AND MUC1 AND THEIR USES | |
| CO2021016982A2 (en) | Methods of using a bispecific antigen-binding construct targeting her2 for the treatment of bile duct cancers | |
| BR112022020716A2 (en) | ANTI-TUMOR ANTIBODIES ASSOCIATED WITH ANTIGEN AND THEIR USES |